
### [MONDO:0005168](http://purl.obolibrary.org/obo/MONDO_0005168)
**Label:** neoplasm of immature b and T cells

**Subclasses:** [MONDO:0014241](http://purl.obolibrary.org/obo/MONDO_0014241) (leukemia, acute lymphoblastic, susceptibility to, 3), [MONDO:0007243](http://purl.obolibrary.org/obo/MONDO_0007243) (Burkitts lymphoma), [MONDO:0013108](http://purl.obolibrary.org/obo/MONDO_0013108) (all), [MONDO:0013109](http://purl.obolibrary.org/obo/MONDO_0013109) (ALL2), [MONDO:0020511](http://purl.obolibrary.org/obo/MONDO_0020511) (precursor b-cell acute lymphoblastic leukemia), [MONDO:0004967](http://purl.obolibrary.org/obo/MONDO_0004967) (acute lymphoblastic leukemia (disease)), [MONDO:0020512](http://purl.obolibrary.org/obo/MONDO_0020512) (precursor T-cell acute lymphoblastic leukemia), [MONDO:0009539](http://purl.obolibrary.org/obo/MONDO_0009539) (lymphoblastic leukemia, acute, with lymphomatous features), 

**Corr. equiv. classes:** [OMIM:613067](http://purl.obolibrary.org/obo/OMIM_613067), [Orphanet:99860](http://www.orpha.net/ORDO/Orphanet_99860), [Orphanet:99861](http://www.orpha.net/ORDO/Orphanet_99861), [OMIM:615545](http://purl.obolibrary.org/obo/OMIM_615545), [Orphanet:543](http://www.orpha.net/ORDO/Orphanet_543), [OMIM:113970](http://purl.obolibrary.org/obo/OMIM_113970), [Orphanet:513](http://www.orpha.net/ORDO/Orphanet_513), [OMIM:613065](http://purl.obolibrary.org/obo/OMIM_613065), [OMIM:247640](http://purl.obolibrary.org/obo/OMIM_247640), 

**Class expressions from DL-Learner:**

- [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 25.61%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 25.45%
- [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) 24.84%
- [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 23.43%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 23.43%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 23.37%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 23.27%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 23.27%
- [HP:0000118](http://purl.obolibrary.org/obo/HP_0000118) (Phenotypic abnormality) 23.24%
- Thing 23.24%
- [HP:0000001](http://purl.obolibrary.org/obo/HP_0000001) (All) 23.24%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) 20.39%
- [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 20.38%
- [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 20.38%
- [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) 18.65%


